Autoantibodies testing in autoimmunity: Diagnostic, prognostic and classification value.

[1]  Radin Massimo,et al.  Identifying subsets of patients with undifferentiated connective tissue disease: Results from a prospective, real-world experience using particle-based multi-analyte technology. , 2023, Autoimmunity reviews.

[2]  S. Platzgummer,et al.  Comparison of current methods for anti‐dsDNA antibody detection and reshaping diagnostic strategies , 2022, Scandinavian journal of immunology.

[3]  C. Pineau,et al.  Serologic phenotypes distinguish systemic lupus erythematosus patients developing interstitial lung disease and/or myositis , 2022, Lupus.

[4]  Marcus John Beasley,et al.  Are IF-ANA the guiding light for SLE classification in the real-world setting? , 2022, Autoimmunity reviews.

[5]  J. Guthridge,et al.  The promise of precision medicine in rheumatology , 2022, Nature Medicine.

[6]  M. Papp,et al.  Serological biomarkers for management of primary sclerosing cholangitis , 2022, World journal of gastroenterology.

[7]  T. Karlsen,et al.  EASL Clinical Practice Guidelines on Sclerosing Cholangitis. , 2022, Journal of hepatology.

[8]  May Y. Choi,et al.  Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort , 2022, Annals of the Rheumatic Diseases.

[9]  C. Bonroy,et al.  Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results , 2022, RMD Open.

[10]  X. Bossuyt,et al.  Impact of autoimmune serology test results on RA classification and diagnosis , 2022, Journal of translational autoimmunity.

[11]  X. Bossuyt,et al.  Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus , 2021, Journal of translational autoimmunity.

[12]  O. Rekvig.  The Anti-DNA Antibodies: Their Specificities for Unique DNA Structures and Their Unresolved Clinical Impact—A System Criticism and a Hypothesis , 2022, Frontiers in Immunology.

[13]  M. Borghi,et al.  Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One , 2021, Frontiers in Immunology.

[14]  A. Nakajima,et al.  Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents , 2021, Drugs.

[15]  T. Geiser,et al.  Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts , 2021, BMJ Open Respiratory Research.

[16]  M. Papp,et al.  Editorial: serologic antibodies in primary sclerosing cholangitis – a tell‐tale sign of compromised gut‐liver immunity? , 2020, Alimentary pharmacology & therapeutics.

[17]  P. Meroni,et al.  Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases , 2020, Nature Reviews Rheumatology.

[18]  G. Parati,et al.  Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome , 2020, Frontiers in Immunology.

[19]  M. Mahler,et al.  Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis , 2020, Clinical chemistry and laboratory medicine.

[20]  J. Sparks,et al.  Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease. , 2020, Autoimmunity reviews.

[21]  H. Johnsen,et al.  Diagnostics of Hereditary Connective Tissue Disorders by Genetic Next-Generation Sequencing. , 2019, Genetic testing and molecular biomarkers.

[22]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[23]  M. Fritzler,et al.  The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study , 2019, Front. Immunol..

[24]  Anthony P Fernandez.  Connective Tissue Disease: Current Concepts. , 2019, Dermatologic clinics.

[25]  May Y. Choi,et al.  Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort , 2019, Arthritis care & research.

[26]  May Y. Choi,et al.  The Utilization of Autoantibodies in Approaches to Precision Health , 2018, Front. Immunol..

[27]  P. D. de Groot,et al.  New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats , 2018, Haematologica.

[28]  P. Emery,et al.  Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status , 2018, Annals of the rheumatic diseases.

[29]  W. Wuyts,et al.  Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias , 2018, Lung.

[30]  P. Verschueren,et al.  Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis , 2018, Annals of the rheumatic diseases.

[31]  Y. Shoenfeld,et al.  Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies , 2017, Clinical chemistry and laboratory medicine.

[32]  T. Karlsen,et al.  Primary sclerosing cholangitis - a comprehensive review. , 2017, Journal of hepatology.

[33]  Joyce S Lee,et al.  Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease , 2015, Respiration.

[34]  D. Lynch,et al.  An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features , 2015, European Respiratory Journal.

[35]  M. Gershwin,et al.  The diagnosis of primary biliary cirrhosis. , 2014, Autoimmunity reviews.

[36]  Torsten Witte,et al.  International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies , 2013, Annals of the rheumatic diseases.

[37]  J. Smolen,et al.  Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review , 2013, Annals of the rheumatic diseases.

[38]  H. Collard,et al.  Update on the diagnosis and classification of ILD , 2013, Current opinion in pulmonary medicine.

[39]  S. Bombardieri,et al.  Analysis of the evolution of UCTD to defined CTD after a long term follow-up. , 2013, Clinical and experimental rheumatology.

[40]  A. Fischer,et al.  Interstitial lung disease in connective tissue disorders , 2012, The Lancet.

[41]  D. Lynch,et al.  Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. , 2012, Respiratory medicine.

[42]  M. Petri,et al.  Systemic lupus erythematosus one disease or many? , 2012, Autoimmunity reviews.

[43]  R. Steele,et al.  Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis , 2012, Arthritis care & research.

[44]  D. Bogdanos,et al.  Disease-specific autoantibodies in primary biliary cirrhosis. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[45]  D. Vergani,et al.  PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. , 2010, Journal of autoimmunity.

[46]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[47]  S. Platzgummer,et al.  Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test , 2010, Lupus.

[48]  I. Mackay,et al.  Autoimmune liver serology: current diagnostic and clinical challenges. , 2008, World journal of gastroenterology.

[49]  S. Bombardieri,et al.  Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? , 2005, The Journal of rheumatology.

[50]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[51]  H. Paulus,et al.  Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. , 1991, The Journal of rheumatology.

[52]  D. Alarcón-Segovia,et al.  Systemic lupus erythematosus. Differences between patients who do, and who do not, fulfill classification criteria at the time of diagnosis. , 1980, The Journal of rheumatology.